Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study
**Background:** Recent evidence suggests that integrase strand transfer inhibitors are associated with greater weight gain than protease inhibitors in patients with human immunodeficiency virus (HIV-1). **Objectives:** To describe demographic and clinical characteristics of insured patients with HI...
Main Authors: | Bruno Emond, Carmine Rossi, Aurélie Côté-Sergent, Keith Dunn, Patrick Lefebvre, Marie-Hélène Lafeuille, Prina Donga |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2021-06-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://jheor.scholasticahq.com/article/24535-weight-change-and-predictors-of-weight-change-among-patients-initiated-on-darunavir-cobicistat-emtricitabine-tenofovir-alafenamide-or-bictegravir-emtr.pdf |
Similar Items
-
Treatment Patterns and Predictors of Adherence in HIV Patients Receiving Single- or Multiple-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide
by: Chow W, et al.
Published: (2020-11-01) -
Bictegravir, Emtricitabine & Tenofovir Alafenamide-associated Acute Pancreatitis
by: Abdulmajeed Alharbi
Published: (2023-05-01) -
Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical Practice
by: Canetti D, et al.
Published: (2023-12-01) -
Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/ Emtricitabine/Tenofovir Alafenamide
by: Franco Maggiolo, et al.
Published: (2022-11-01) -
Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era
by: Squillace N, et al.
Published: (2018-10-01)